| Mr Kevin Dean Holt, MS PT | |
|
310 Mid Continent Plz Ste 185, West Memphis, AR 72301-1700 | |
| (870) 732-2828 | |
| Not Available |
| Full Name | Mr Kevin Dean Holt |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 29 Years |
| Location | 310 Mid Continent Plz Ste 185, West Memphis, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659704120 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT1846 (Arkansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Holt Therapy And Wellness, Pllc | 3375868862 | 6 |
News Archive
In the September 1st issue of G&D, Dr. Karen Oegema (UCSD) and colleagues identify the molecular basis of the lethal developmental disorder, hydrolethalus syndrome, and reveal that hydrolethalus syndrome actually belongs to the emerging class of human ciliopathy diseases.
Over the past several decades, neurostimulation techniques such as transcranial direct current stimulation (tDCS) have gradually gained favour in the public eye. In a new report, published yesterday in the prestigious scientific journal Neuron, IRCM ethics experts raise important questions about the rising tide of tDCS coverage in the media, while regulatory action is lacking and ethical issues need to be addressed.
A clinical research study is being conducted for patients with Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS), a chronic bladder disorder characterized by intense pelvic pain, urinary frequency-urgency, and pain during sexual intimacy (www.PainfulBladderStudy.org). It is estimated that as many as 1.3 million people in the U.S. have been diagnosed with this disease and many more remain undiagnosed.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.
Cerus Corporation announced today that it has signed an agreement to acquire BioOne Corporation's commercialization rights for the INTERCEPT Blood System for platelets and plasma, subject to approval of the transaction by BioOne's shareholders. In 2004 and 2005, Cerus and its partner at the time, Baxter International, licensed the commercialization rights for INTERCEPT platelets and plasma to BioOne for an Asian territory, which included China, Japan, Taiwan, Singapore, Korea, Thailand and Vietnam.
› Verified 1 days ago
| Provider Name | Holt Therapy And Wellness, Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1891128260 PECOS PAC ID: 3375868862 Enrollment ID: O20150312002148 |
News Archive
In the September 1st issue of G&D, Dr. Karen Oegema (UCSD) and colleagues identify the molecular basis of the lethal developmental disorder, hydrolethalus syndrome, and reveal that hydrolethalus syndrome actually belongs to the emerging class of human ciliopathy diseases.
Over the past several decades, neurostimulation techniques such as transcranial direct current stimulation (tDCS) have gradually gained favour in the public eye. In a new report, published yesterday in the prestigious scientific journal Neuron, IRCM ethics experts raise important questions about the rising tide of tDCS coverage in the media, while regulatory action is lacking and ethical issues need to be addressed.
A clinical research study is being conducted for patients with Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS), a chronic bladder disorder characterized by intense pelvic pain, urinary frequency-urgency, and pain during sexual intimacy (www.PainfulBladderStudy.org). It is estimated that as many as 1.3 million people in the U.S. have been diagnosed with this disease and many more remain undiagnosed.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.
Cerus Corporation announced today that it has signed an agreement to acquire BioOne Corporation's commercialization rights for the INTERCEPT Blood System for platelets and plasma, subject to approval of the transaction by BioOne's shareholders. In 2004 and 2005, Cerus and its partner at the time, Baxter International, licensed the commercialization rights for INTERCEPT platelets and plasma to BioOne for an Asian territory, which included China, Japan, Taiwan, Singapore, Korea, Thailand and Vietnam.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Kevin Dean Holt, MS PT 1002 Georgetown Cv, West Memphis, AR 72301-3863 Ph: (870) 732-8710 | Mr Kevin Dean Holt, MS PT 310 Mid Continent Plz Ste 185, West Memphis, AR 72301-1700 Ph: (870) 732-2828 |
News Archive
In the September 1st issue of G&D, Dr. Karen Oegema (UCSD) and colleagues identify the molecular basis of the lethal developmental disorder, hydrolethalus syndrome, and reveal that hydrolethalus syndrome actually belongs to the emerging class of human ciliopathy diseases.
Over the past several decades, neurostimulation techniques such as transcranial direct current stimulation (tDCS) have gradually gained favour in the public eye. In a new report, published yesterday in the prestigious scientific journal Neuron, IRCM ethics experts raise important questions about the rising tide of tDCS coverage in the media, while regulatory action is lacking and ethical issues need to be addressed.
A clinical research study is being conducted for patients with Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS), a chronic bladder disorder characterized by intense pelvic pain, urinary frequency-urgency, and pain during sexual intimacy (www.PainfulBladderStudy.org). It is estimated that as many as 1.3 million people in the U.S. have been diagnosed with this disease and many more remain undiagnosed.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.
Cerus Corporation announced today that it has signed an agreement to acquire BioOne Corporation's commercialization rights for the INTERCEPT Blood System for platelets and plasma, subject to approval of the transaction by BioOne's shareholders. In 2004 and 2005, Cerus and its partner at the time, Baxter International, licensed the commercialization rights for INTERCEPT platelets and plasma to BioOne for an Asian territory, which included China, Japan, Taiwan, Singapore, Korea, Thailand and Vietnam.
› Verified 1 days ago
Joey Britt, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 200 W Broadway St, West Memphis, AR 72301 Phone: 870-394-7000 Fax: 870-394-7001 | |
Bryce Newsome, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 610 N Missouri St Ste 1, West Memphis, AR 72301 Phone: 870-400-0179 | |
Mary Gay Collins, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 620 Thompson Ave, West Memphis, AR 72301 Phone: 870-702-4911 Fax: 870-702-6386 | |
Ben Charles, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 205 Ingram Blvd, West Memphis, AR 72301 Phone: 870-735-2737 | |
Micah Lynette Smithmier, MPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 620 Thompson Ave, West Memphis, AR 72301 Phone: 870-702-4911 | |
Mrs. Joanna Caldarulo Jeanfreau, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 413 W Tyler Ave, West Memphis, AR 72301 Phone: 870-733-1200 Fax: 870-732-3269 | |
Maria Gigi Floresca, Physical Therapist Medicare: Medicare Enrolled Practice Location: 610 S Avalon St, West Memphis, AR 72301 Phone: 870-400-3481 |